Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2023-01-24 Report Publication Anno…
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
GENFIT annonce son calendrier financier pour 2023
Report Publication Announcement Classification · 98% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and its primary purpose is to announce the "calendrier financier pour 2023" (financial calendar for 2023). This calendar lists future dates for publishing revenue, annual results (including the 20-F filing), interim results, and the AGM. Since the document's core function is to announce *when* other reports will be released, rather than being the report itself (like a 10-K or IR), it fits the definition of a Report Publication Announcement (RPA). The document is substantial enough (over 7,000 characters) that it is not a simple RNS fallback, but the content is purely an announcement schedule.
2023-01-24 French
GENFIT Announces 2023 Financial Calendar
Report Publication Announcement Classification · 98% confidence The document is explicitly titled "PRESS RELEASE" and its primary content is the announcement of the company's "2023 Financial Calendar." This calendar details future dates for the publication of financial results (revenue, cash position, full-year statements) and the Annual Shareholders Meeting. Since the document is an announcement about *when* reports will be published, rather than the reports themselves (like 10-K or IR), it fits the definition of a Report Publication Announcement (RPA). It is not a general regulatory filing (RNS) because a more specific category (RPA) applies to announcements of report publication schedules. The document length (6671 chars) is substantial enough that it's not a simple placeholder, but its function is purely to announce future publications.
2023-01-24 English
GENFIT annonce sa participation aux prochaines conférences investisseurs
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and its primary content announces the company's upcoming participation in several investor conferences (JPMorgan Healthcare Conference, Biotech Showcase, ODDO BHF Forum, etc.) scheduled for January and February 2023, with one past event mentioned from April 2022. This type of announcement, detailing management's schedule for meeting with investors and analysts, is characteristic of investor relations communications that do not constitute a full financial report (like 10-K or IR) or a formal earnings release (ER). Since the document is announcing future events and providing general company information, it best fits the category for Investor Presentation (IP) if it were a deck, or more generally, a communication aimed at investors about corporate activities. However, none of the definitions perfectly capture a simple schedule announcement. Given the context of investor engagement and the nature of the content (listing conferences where management will present), it is closely related to Investor Presentation (IP) materials, but since it is just an announcement of attendance, it is often categorized as a general Regulatory Filing (RNS) if no other specific category fits, or sometimes grouped with Investor Relations materials. Looking at the options, this is not a formal report, transcript, or specific transaction notice. It is an announcement about investor engagement activities. In many databases, such announcements are classified under general regulatory filings or investor relations updates. Since it is a press release detailing future investor engagement, and not a formal presentation itself, 'RNS' (Regulatory Filings - general fallback) is the most appropriate general classification, although 'IP' (Investor Presentation) is conceptually close if the announcement implies that presentations will be given. Given the strict definitions, and that this is a press release announcing participation in external events, RNS is the safest fallback for an announcement that doesn't fit the specific report types.
2023-01-05 French
GENFIT to Participate in Upcoming Investor Conferences
Report Publication Announcement Classification · 99% confidence The document is explicitly titled "PRESS RELEASE" and its primary content announces that GENFIT management will participate in several upcoming investor conferences (JPMorgan Healthcare Conference, Biotech Showcase, ODDO BHF Forum, etc.) during January and February 2023. This type of announcement, detailing future investor engagement events, is not a core financial report (like 10-K, IR, ER) nor a specific regulatory filing like a Director's Dealing or Dividend Notice. It is an announcement intended for investors regarding corporate outreach activities. While it is a form of investor relations communication, it doesn't fit perfectly into the provided specific categories like Investor Presentation (IP) or Earnings Release (ER). Since it is a general announcement about corporate activities and investor engagement schedules, and given the available options, it most closely aligns with a general regulatory/investor announcement that doesn't fit elsewhere, or perhaps an announcement about future presentations. However, since it is purely an announcement of *participation* in external conferences, and not the presentation material itself, the most appropriate general category for non-specific corporate announcements that don't fit the highly specific financial/regulatory codes is RNS (Regulatory Filings/General Announcements). If 'Investor Relations Announcement' were an option, it would be preferred, but RNS serves as the best fallback for general corporate news releases that aren't earnings or formal reports.
2023-01-05 English
GENFIT : Le Pipeline Day met en valeur un portefeuille de produits diversifié dans des maladies hépatiques manquant de solutions thérapeutiques
AGM Information Classification · 95% confidence The document is titled "GENFIT : Le Pipeline Day met en valeur un portefeuille de produits diversifié..." and explicitly mentions that it provides a review of the main points communicated during the "Pipeline Days" event. It details clinical pipeline updates, market potential, and expert speakers. The text also explicitly states: "Un enregistrement vidéo des deux Pipeline Days organisés à Paris (le 5 octobre 2022) et New York (le 19 octobre 2022) est désormais disponible et peut être consulté sur la page « Evénements et Présentations »..." Furthermore, the final sentence states: "Lors de nos « Pipeline Days », nous avons été ravis de procéder à une revue exhaustive de nos nouveaux programmes..." This content strongly indicates that the document is a summary or presentation material related to an Annual General Meeting (AGM) or a similar investor/analyst event focused on the company's pipeline and strategy review, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Given the options, 'AGM-R' (AGM Information) is the most appropriate classification for materials presented at a dedicated 'Pipeline Day' event aimed at investors and analysts, which often overlaps in function with AGM presentations or investor days.
2022-11-17 French
GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases
Investor Presentation Classification · 99% confidence The document is a detailed press release dated November 17, 2022, summarizing highlights from a 'Pipeline Day' event. It discusses clinical progress, R&D strategy, market potential for various liver disease treatments (PBC, ACLF, HE, CCA, UCD/OAD), and quotes the CEO. This content structure—a comprehensive update on pipeline assets, strategic direction, and expert commentary, often released following an investor event—is characteristic of an Investor Presentation (IP) or a detailed Management Discussion/Analysis (MDA) if it were part of a formal filing. Since it is presented as a news release summarizing an event focused on strategy and pipeline deep dives, and given the options, 'Investor Presentation' (IP) is the most fitting category for this type of forward-looking, detailed strategic update aimed at investors, even though it is formatted as a press release. It is not a formal regulatory filing like 10-K or IR, nor is it just a brief earnings release (ER).
2022-11-17 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.